<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-3-1">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Eltrombopag in severe aplastic anaemia: <br />haematological-monitoring parameters
			</div>


			<div class="content-container">

				<ul>
					<li><span>The dosage regimen of eltrombopag should be modified based on platelet counts</span></li>
					<li><span>During therapy, complete blood counts (CBCs) with differentials (including platelet counts) should be assessed weekly until a stable platelet count has been achieved</span>
						<ul>
							<li><span>CBCs with differentials should be obtained monthly thereafter</span></li>
						</ul>
					</li>
					<li><span>CBCs with differentials should be obtained weekly for at least 4 weeks after discontinuation of eltrombopag</span></li>
				</ul>

			</div>

		</div>




		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/Promacta-PI-2014"><span>GlaxoSmithKline. Promacta (eltrombopag) tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ul>

		</div>


		

	</div>
</div>